LAM Pilot Study With Imatinib Mesylate

Exclusion Criteria

• •Current or planned pregnancy or lactation
• •Unwillingness to discontinue sirolimus
• •Change in the dose or use of sirolimus within the past month
• •Inability to perform spirometry
• •Allergy or intolerance of albuterol and/or ipratropium
• •Other serious illness that would impact the outcome of the study including cancer that has not received curative therapy, Grade III/IV cardiac problems as defined by the New York Heart Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6 months of study), uncontrolled diabetes, chronic renal disease, chronic liver disease, or active uncontrolled infection
• •Current lung transplant
• •Known diagnosis of human immunodeficiency virus (HIV) infection
• •Current cigarette smoking
• •Required use of warfarin, ketoconazole, itraconazole, clarithromycin, or rifampin during the 2 months of the study.
• •Unwillingness to avoid grapefruit juice or St. Johns Wort during the study.
• •Planned surgery during the 2 months of the study.
• •Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.
• •Patient has received and other investigational agents within 28 days of first day of study drug dosing.